Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**6-(cyclohexylsulfanyl)-1-(ethoxymethyl)-5-(1-methylethyl)pyrimidine-2,4(1H,3H)-dione** (also known as TNK‑6123) is a synthetic small molecule belonging to the class of aryl thioethers and structurally related to pyrimidine diones. It is an analog of emivirine with reported improved activity against drug-resistant HIV mutants. The compound has been studied as an experimental antiviral agent targeting HIV but does not have approved indications or established clinical use[9][2][7]. Its mechanism of action is presumed to involve inhibition of HIV reverse transcriptase, similar to other non-nucleoside reverse transcriptase inhibitors (NNRTIs), though direct evidence for this specific compound's target profile remains limited in public sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-(cyclohexylsulfanyl)-1-(ethoxymethyl)-5-(1-methylethyl)pyrimidine-2,4(1H,3H)-dione.